SavedAdd your journal

Journals / Klinik Tıp Pediatri Dergisi / 2026 / Cilt: 9 Sayı: 2

Subcutaneous and Sublingual Immunotherapy by Inhaler Allergens

İnhalen Allerjenlerle Subkutan ve Sublingual İmmünoterapi

Prof. Dr. Nerin N. Bahçeciler
Pages
165–170
Publication Date
2017-03-15
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

On the other hand, data in literature suggests that both methods are highly evidential and selection of sublingual or SCIT should be tailored based on compliance, availability, and co-decision of doctor-patient.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Abstract Currently, it is demonstrated that allergen spesific immunotherapy (SIT) is theonly treatment that capable to change the natural course or allergic diseases such asallergic rhinitis and asthma.
📊
Key Findings & Data:Although, subcutaneous immunotherapy (SCIT) is approved as the gold standart treatment, sublingual immunotherapy (SLIT) has been shown to demonstrate similar efficacy with more safety.
💡
Conclusion & Impact:On the other hand, data in literature suggests that both methods are highly evidential and selection of sublingual or SCIT should be tailored based on compliance, availability, and co-decision of doctor-patient.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Subkutan immünoterap · sublingual immünoterapi · ubcutaneous immunotherapy

Abstract

Abstract Currently, it is demonstrated that allergen spesific immunotherapy (SIT) is theonly treatment that capable to change the natural course or allergic diseases such asallergic rhinitis and asthma. Although, subcutaneous immunotherapy (SCIT) is approved as the gold standart treatment, sublingual immunotherapy (SLIT) has been shown to demonstrate similar efficacy with more safety. Cochrane systematic reviews and metaanalyses, published to date has demonstrated the efficacy of both SLIT and SCIT in patients withallergic rhinitis and asthma sensitizied to either perrenial or seasonal airborne allergens. Although, both methods are demonstrated to be clinically efficient and to induce immunological tolerance in many studies, literature is scarce comparing SLITversus SCIT head to head in terms of efficacy and immune tolerance induction. On the other hand, data in literature suggests that both methods are highly evidential and selection of sublingual or SCIT should be tailored based on compliance, availability, and co-decision of doctor-patient.

Özet

Öz Günümüzde allerjik rinit ve astım gibi solunum yolu allerjik hastalıklarının tedavisinde hastalığın doğal seyrini değiştirebilen tek tedavi yönteminin allerjen spesifik immünoterapi (SIT) olduğu kanıtlanmıştır. Subkutan immünoterapi (SCIT) altın standart tedavi olarak kabul görmesine karşın sublingual immünoterapinin (SLIT)son 3 dekadda benzer etkinliği olan emniyetli bir tedavi yöntemi olduğu kanıtlanmıştır. Günümüze dek yayınlanmış Cochrane sistematik derleme ve meta analizlerde gerek SCIT gerekse SLIT’ın mevsimsel veya perennial inhalen allerjenlere duyarlı allerjik rinit ve astımlı olgulardaki etkinliği gösterilmiştir. Her iki tedavi yöntemi ile semptom ve ilaç kullanımında anlamlı azalma olduğu ve immünolojik toleransı indüklediği birçok araştırmada kanıtlanmış olmasına rağmen, bu iki yöntemin etkinlik ve immün tolerans yönünden birebir karşılaştırıldığı çalışmalar pek azdır. Öte yandan literatürdeki veriler her iki yöntemin de yüksek kanıt değerinde olup,sublingual veya subkutan immünoterapi seçiminin uygulanabilirlilik, ulaşılabilirlilik ve hasta hekim ortak kararı ile uygulanmasını önermektedir.

🔖

Cite This Article

Bahçeciler, P. D. N. N. (2017). Subcutaneous and Sublingual Immunotherapy by Inhaler Allergens. Klinik Tıp Pediatri Dergisi, Cilt: 9 Sayı: 2, 165–170. https://ajindex.com/articles/1595068

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (125)

  1. Kaynaklar 1.Asher MI, Montefort S, Björksten B, Lai CK, Strachan DP, Wei-land SK, et al. Worldwide time trends in the prevalence ofsymptoms of asthma, allergic rhinoconjunctivitis, and eczema inchildhood: ISAAC Phases One and Three repeat multicountrycross-sectional surveys. Lancet. 2006
  2. Ait-Khaled N, Odhiambo J, Pearce N, Adjoh KS, Maesano IA, Ben-habyles B, et al. Prevalence of symptoms of asthma, rhinitis andeczema in 13- to 14-year-old children in Africa: the Internatio-nal Study of Asthma and Allergies in Childhood Phase III. Allergy.2007
  3. 62(3):247-58. 3.Bousquet, J, Lockey R.F, Malling H.J WHO position paper. Al-lergen immunotherapy: therapeutic vaccines for allergic disea-ses. Allergy. 1998
  4. 53, 1-42 4.Cox L. Allergen immunotherapy and asthma: efficacy, safety, andother considerations. Allergy Asthma Proc. 2008
  5. 29(6):580-9.doi: 10.2500/aap.2008.29.3162. 5.Cox L, Li J., Lockey F, Richard L. Allergen immunotherapy: Apractice parameter second update. J Allergy Clin Immunol.2007
  6. Bernstein DI, Wanner M, Borish L, Liss GM
  7. ImmunotherapyCommittee, American Academy of Allergy, Asthma and Immuno-logy. Twelve-year survey of fatal reactions to allergen injectionsand skin testing: 1990-2001. J Allergy Clin Immunol.2004
  8. 113(6):1129-36. 7.Bousquet J., Lockey R., Malling H.J ve ark. Allergen immunot-herapy: Therapeutic vaccines for allergic diseases. World healthOrganisation.American Academy of Allergy, Asthma and Immu-nology. Annals of Allergy Asthma and Immunology. 1998
  9. 81,401-405. 8.Calderon MA, Alves B, Jacobson M, Hurwitz B, Sheikh A, Dur-ham S. Allergen injection immunotherapy for seasonal allergicrhinitis. Cochrane Database Syst Rev. 2007
  10. :CD001936. 9.Passalaqua G, Durham SR. Allergic rhinitis and its impact on asth-ma update: allergen immunotherapy. Journal of Allergy and Cli-nical Immunology. 2007
  11. 119, 881-891. 10.Frew AJ, Powell RJ, Corrigan CJ, Durham SR
  12. UK Immunothe-rapy Study Group. [Efficacy and safety of specific immunothe-rapy with SQ allergen extract in treatment-resistant seasonal al-lergic rhinoconjunctivitis]. J Allergy Clin Immunol.2006
  13. 117(2):319-25. 11.Powell RJ, Frew A.J., Corrigan CJ, et al. Effect of grass pollenimmunotherapy with Durham Sr,Alutard SQ on quality of life inseasonal allergic rhinoconjunctivitis. Allergy 2007
  14. 62, 1335-1338. 12.Abramson M., Puy R., Weiner J.M. (1995) Is allergen immunot-herapy effective in asthma? A meta-analysis of randomized con-trolled trials. American Journal of Respiratory and Critical CareMedicine. 151, 969-974 13.Abramson MJ, Puy RM, Weiner JM. [Injection allergen immu-notherapy for asthma]. Cochrane Database Syst Rev. 2010 Aug4
  15. :CD001186. doi: 10.1002/14651858.CD001186.pub2. 14.Wilson DR, Lima MT, Durham SR. [Sublingual immunotherapyfor allergic rhinitis: systematic review and meta-analysis]. Al-lergy. 2005
  16. 60(1):4-12. 15.Penagos M, Passalacqua G, Compalati E, Baena-Cagnani CE,Orozco S, Pedroza A, et al. [Metaanalysis of the efficacy of sub-lingual immunotherapy in the treatment of allergic asthma in pe-diatric patients, 3 to 18 years of age]. Chest. 2008
  17. 133(3):599-609. 16.Calamita Z, Saconato H, Pelá AB, Atallah AN. [Efficacy of sub-lingual immunotherapy in asthma: systematic review of rando-mized-clinical trials using the Cochrane Collaboration method].Allergy. 2006
  18. 61(10):1162-72. 17.Bufe A. [Usefulness of sublingual immunotherapy in children.Drugs Today (Barc)]. 2008
  19. 44 Suppl B:61-3. 18.Bacharier LB, Boner A, Carlsen KH, Eigenmann PA, FrischerT, Götz M, et al. [Diagnosis and treatment of asthma in child-hood: a PRACTALL consensus report]. Allergy. 2008
  20. 63(1):5-34. 19.Penagos M, Compalati E, Tarantini F, Baena-Cagnani R, Hu-erta J, Passalacqua G, et al. [Efficacy of sublingual immunothe-rapy in the treatment of allergic rhinitis in pediatric patients 3to 18 years of age: a meta-analysis of randomized, placebo-con-trolled, double-blind trials]. Ann Allergy Asthma Immunol.2006
  21. 97(2):141-8. 20.Pradalier A, Basset D, Claudel A, Couturier P, Wessel F, Gal-vain S, et al. [Sublingual-swallow immunotherapy (SLIT) with astandardized five-grass-pollen extract (drops and sublingual tab-lets) versus placebo in seasonal rhinitis]. Allergy. 1999
  22. 54(8):819-28. 21.La Rosa M, Ranno C, André C, Carat F, Tosca MA, CanonicaGW. [Double-blind placebo-controlled evaluation of sublingu-al-swallow immunotherapy with standardized Parietaria judai-ca extract in children with allergic rhinoconjunctivitis]. J AllergyClin Immunol. 1999
  23. Durham SR, Yang WH, Pedersen MR, Johansen N, Rak S. [Sub-lingual immunotherapy with once-daily grass allergen tablets:a randomized controlled trial in seasonal allergic rhinoconjunc-tivitis]. J Allergy Clin Immunol. 2006
  24. 117(4):802-9. 23.Dahl R, Kapp A, Colombo G, de Monchy JG, Rak S, EmmingerW, et al. [Efficacy and safety of sublingual immunotherapy withgrass allergen tablets for seasonal allergic rhinoconjunctivitis].J Allergy Clin Immunol. 2006
  25. 118(2):434-40. 24.Bufe A, Eberle P, Franke-Beckmann E, Funck J, Kimmig M, Kli-mek L, et al. [Safety and efficacy in children of an SQ-standar-dized grass allergen tablet for sublingual immunotherapy]. J Al-lergy Clin Immunol. 2009
  26. 123(1):167-173.e7. doi:10.1016/j.jaci.2008.10.044. 25.Didier A, Malling HJ, Worm M, Horak F, Jäger S, Montagut A,et al. [Optimal dose, efficacy, and safety of once-daily sublingu-al immunotherapy with a 5-grass pollen tablet for seasonal al-lergic rhinitis]. J Allergy Clin Immunol. 2007
  27. 120(6):1338-45. 26.Dahl R, Stender A, Rak S. [Specific immunotherapy with SQ stan-dardized grass allergen tablets in asthmatics with rhinoconjunc-tivitis]. Allergy. 2006
  28. 61(2):185-90. 27.Lue KH, Lin YH, Sun HL, Lu KH, Hsieh JC, Chou MC. [Clini-cal and immunologic effects of sublingual immunotherapy in asth-matic children sensitized to mites: a double-blind, randomized,placebo-controlled study]. Pediatr Allergy Immunol.2006
  29. 17(6):408-15. 28.Pham-Thi N1, Scheinmann P, Fadel R, Combebias A, Andre C.[Assessment of sublingual immunotherapy efficacy in children withhouse dust mite-induced allergic asthma optimally controlled bypharmacologic treatment and mite-avoidance measures]. Pedi-atr Allergy Immunol. 2007
  30. 18(1):47-57. 29.Moreno-Ancillo A, Moreno C, Ojeda P, Domínguez C, Baraso na MJ, García-Cubillana A, et al. [Efficacy and quality of life withonce-daily sublingual immunotherapy with grasses plus olive pol-len extract without updosing]. J Investig Allergol Clin Immunol.2007
  31. 17(6):399-405. 30.Amar SM, Harbeck RJ, Sills M, Silveira LJ, O'Brien H, NelsonHS. [Response to sublingual immunotherapy with grass pollenextract: monotherapy versus combination in a multiallergen ext-ract]. J Allergy Clin Immunol. 2009
  32. 124(1):150-156.e1-5. doi:10.1016/j.jaci.2009.04.037. 31.Malling H. [Position paper: Immunotherapy with hymenopteravenoms. (EAACI) The European Academy of Allergology and Cli-nical Immunology]. Allergy. 1993
  33. 48(14 Suppl):36-46. 32.Bousquet J, Hejjaoui A, Dhivert H, Clauzel AM, Michel FB. [Im-munotherapy with a standardized Dermatophagoides pteronys-sinus extract. Systemic reactions during the rush protocol in pa-tients suffering from asthma]. J Allergy Clin Immunol.1989
  34. 83(4):797-802. 33.Lima MT, Wilson D, Pitkin L, Roberts A, Nouri-Aria K, Jacob-son M, et al. [Grass pollen sublingual immunotherapy for sea-sonal rhinoconjunctivitis: a randomized controlled trial]. Clin ExpAllergy. 2002
  35. 32(4):507-14. 34.Alvarez-Cuesta E, Berges-Gimeno P, González-Mancebo E, Fer-nández-Caldas E, Cuesta-Herranz J, Casanovas M. [Sublingu-al immunotherapy with a standardized cat dander extract: eva-luation of efficacy in a double blind placebo controlled study].Allergy. 2007
  36. 62(7):810-7. 35.Cox LS, Larenas Linnemann D, Nolte H, Weldon D, Finegold I,Nelson HS. [Sublingual immunotherapy: a comprehensive revi-ew]. J Allergy Clin Immunol. 2006
  37. 117(5):1021-35. 36.Dunsky EH, Goldstein MF, Dvorin DJ, Belecanech GA. [Anaphy-laxis to sublingual immunotherapy]. Allergy. 2006Oct
  38. 61(10):1235. 37.Eifan AO, Keles S, Bahceciler NN, Barlan IB. [Anaphylaxis tomultiple pollen allergen sublingual immunotherapy]. Allergy.2007
  39. 62(5):567-8. 38.Blazowski L. [Anaphylactic shock because of sublingual immu-notherapy overdose during third year of maintenance dose. Al-lergy]. 2008
  40. 63(3):374. 39.Windom HH, Lockey RF. [An update on the safety of specific im-munotherapy]. Curr Opin Allergy Clin Immunol. 2008
  41. 8(6):571-6. doi: 10.1097/ACI.0b013e32831845fb. 40.Galip N, Bahceciler N. [Rare adverse events due to house dustmite sublingual immunotherapy in pediatric practice: two casereports]. Immunotherapy. 2015
  42. 7(12):1235-9. doi:10.2217/imt.15.88. 41.Flicker S, Steinberger P, Norderhaug L, Sperr WR, Majlesi Y, Va-lent P, et al. [Conversion of grass pollen allergen-specific humanIgE into a protective IgG(1) antibody]. Eur J Immunol.2002
  43. 32(8):2156-62. 42.van Neerven RJ, Wikborg T, Lund G, Jacobsen B, Brinch-Niel-sen A, Arnved J, e t al. [Blocking antibodies induced by specificallergy vaccination prevent the activation of CD4+ T cells by in-hibiting serum-IgE-facilitated allergen presentation]. J Immunol. 1999
  44. 163 (5):29 44 -52. 43.Jutel M, Akdis M, Budak F, Aebischer-Casaulta C, Wrzyszcz M,Blaser K, et al. [IL-10 and TGF-beta cooperate in the regulatoryT cell response to mucosal allergens in normal immunity and spe-cific immunotherapy]. Eur J Immunol. 2003
  45. 33(5):1205-14. 44.Akdis CA., Blesken T, Akdis M, Wüthrich B, Blaser K. [Role ofinterleukin 10 in specific immunotherapy]. J Clin Invest. 1998
  46. 102(1): 98–106. doi: 10.1172/JCI2250. 45.Creticos PS, Adkinson NF Jr, Kagey-Sobotka A, Proud D, Me-ier HL, Naclerio RM, et al. [Nasal challenge with ragweed pol-len in hay fever patients. Effect of immunotherapy]. J Clin Invest.1985
  47. 76(6):2247-53. 46.Otsuka H, Mezawa A, Ohnishi M, Okubo K, Seki H, Okuda M.[Changes in nasal metachromatic cells during allergen immunot-herapy]. Clin Exp Allergy 1991
  48. 115–119. 47.Marcucci F, Incorvaia C, Sensi L, Di Cara G, Cadario G, Ca-valiere A, et al. [Lack of inflammatory cells in the oral mucosaof subjects undergoing sublingual immunotherapy]. Int J Immu-nopathol Pharmacol. 2008
  49. 21(3):609-13. 48.Bagnasco M, Altrinetti V, Pesce G, Caputo M, Mistrello G, Fa-lagiani P, et al. [Pharmacokinetics of Der p 2 allergen and de-rived monomeric allergoid in allergic volunteers]. Int Arch Al-lergy Immunol. 2005
  50. 138(3):197-202. 49.Bagnasco M, Passalacqua G, Villa G, Augeri C, Flamigni G, Bo-rini E, et al. [Pharmacokinetics of an allergen and a monome-ric allergoid for oromucosal immunotherapy in allergic volun-teers]. Clin Exp Allergy. 2001
  51. 31(1):54-60. 50.Nouri-Aria KT1, Wachholz PA, Francis JN, Jacobson MR, Wal-ker SM, Wilcock LK, et al. [Grass pollen immunotherapy indu-ces mucosal and peripheral IL-10 responses and blocking IgGactivity]. J Immunol. 2004
  52. 172(5):3252-9. 51.Walker SM, Varney VA, Gaga M, Jacobson MR, Durham SR.[Grass pollen immunotherapy: efficacy and safety during a 4-yearfollow-up study]. Allergy. 1995
  53. 50(5):405-13. 52.Bousquet J, Lockey R, Malling HJ, Alvarez-Cuesta E, Canoni-ca GW, Chapman MD, et al. [Allergen immunotherapy: thera-peutic vaccines for allergic diseases. World Health Organizati-on. American academy of Allergy, Asthma and Immunology]. AnnAllergy Asthma Immunol. 1998
  54. 81(5):401-5. 53.Allam JP, Peng WM, Appel T, Wenghoefer M, Niederhagen B,Bieber T, et al. [Toll-like receptor 4 ligation enforces toleroge-nic properties of oral mucosal Langerhans cells]. J Allergy ClinImmunol. 2008
  55. 121(2):368-374.e1. 54.Allam JP, Klein E, Bieber T, Novak N. [Transforming growth fac-tor-beta1 regulates the expression of the high-affinity receptorfor IgE on CD34 stem cell-derived CD1a dendritic cells in vit-ro]. J Invest Dermatol. 2004
  56. 123(4):676-82. 55.Bahceciler NN, Galip N. [Comparing subcutaneous and sublin-gual ımmunotherapy: what do we know?]. Curr Opin Allergy ClinImmunol. 2012
  57. 12(6):640-7. doi: 10. 1097/ ACI.0b013e328358d5f2. 56.Durham SR, Penagos M. [Sublingual or subcutaneous immunot-herapy for allergic rhinitis?]. J Allergy Clin Immunol.2016
  58. 137(2):339-349.e10. doi: 10.1016/j.jaci.2015.12.1298. 57.Jacobsen L, Niggemann B, Dreborg S, Ferdousi HA, Halken S,Høst A, et al. [Specific immunotherapy has long-term preventi-ve effect of seasonal and perennial asthma: 10-year follow-up onthe PAT study]. Allergy. 2007
  59. 62(8):943-8. 58.Eng PA, Borer-Reinhold M, Heijnen IA, Gnehm HP. [Twelve-yearfollow-up after discontinuation of preseasonal grass pollen immu-notherapy in childhood]. Allergy. 2006
  60. 61(2):198-201.59.Durham SR
  61. GT-08 investigators. [Sustained effects of grass pol-len AIT]. Allergy. 2011 Jul
  62. 66 Suppl 95:50-2. doi: 10.1111/j.1398-9995.2011.02639.x. 60.Marogna M, Spadolini I, Massolo A, Canonica GW, Passalac-qua G. [Long-lasting effects of sublingual immunotherapy accor-ding to its duration: a 15-year prospective study]. J Allergy ClinImmunol. 2010
  63. 126(5):969-75. doi: 10.1016/j. jaci.2010.08.030. Kaynaklar 1.Asher MI, Montefort S, Björksten B, Lai CK, Strachan DP, Wei-land SK, et al. Worldwide time trends in the prevalence ofsymptoms of asthma, allergic rhinoconjunctivitis, and eczema inchildhood: ISAAC Phases One and Three repeat multicountrycross-sectional surveys. Lancet. 2006
  64. Ait-Khaled N, Odhiambo J, Pearce N, Adjoh KS, Maesano IA, Ben-habyles B, et al. Prevalence of symptoms of asthma, rhinitis andeczema in 13- to 14-year-old children in Africa: the Internatio-nal Study of Asthma and Allergies in Childhood Phase III. Allergy.2007
  65. 62(3):247-58. 3.Bousquet, J, Lockey R.F, Malling H.J WHO position paper. Al-lergen immunotherapy: therapeutic vaccines for allergic disea-ses. Allergy. 1998
  66. 53, 1-42 4.Cox L. Allergen immunotherapy and asthma: efficacy, safety, andother considerations. Allergy Asthma Proc. 2008
  67. 29(6):580-9.doi: 10.2500/aap.2008.29.3162. 5.Cox L, Li J., Lockey F, Richard L. Allergen immunotherapy: Apractice parameter second update. J Allergy Clin Immunol.2007
  68. Bernstein DI, Wanner M, Borish L, Liss GM
  69. ImmunotherapyCommittee, American Academy of Allergy, Asthma and Immuno-logy. Twelve-year survey of fatal reactions to allergen injectionsand skin testing: 1990-2001. J Allergy Clin Immunol.2004
  70. 113(6):1129-36. 7.Bousquet J., Lockey R., Malling H.J ve ark. Allergen immunot-herapy: Therapeutic vaccines for allergic diseases. World healthOrganisation.American Academy of Allergy, Asthma and Immu-nology. Annals of Allergy Asthma and Immunology. 1998
  71. 81,401-405. 8.Calderon MA, Alves B, Jacobson M, Hurwitz B, Sheikh A, Dur-ham S. Allergen injection immunotherapy for seasonal allergicrhinitis. Cochrane Database Syst Rev. 2007
  72. :CD001936. 9.Passalaqua G, Durham SR. Allergic rhinitis and its impact on asth-ma update: allergen immunotherapy. Journal of Allergy and Cli-nical Immunology. 2007
  73. 119, 881-891. 10.Frew AJ, Powell RJ, Corrigan CJ, Durham SR
  74. UK Immunothe-rapy Study Group. [Efficacy and safety of specific immunothe-rapy with SQ allergen extract in treatment-resistant seasonal al-lergic rhinoconjunctivitis]. J Allergy Clin Immunol.2006
  75. 117(2):319-25. 11.Powell RJ, Frew A.J., Corrigan CJ, et al. Effect of grass pollenimmunotherapy with Durham Sr,Alutard SQ on quality of life inseasonal allergic rhinoconjunctivitis. Allergy 2007
  76. 62, 1335-1338. 12.Abramson M., Puy R., Weiner J.M. (1995) Is allergen immunot-herapy effective in asthma? A meta-analysis of randomized con-trolled trials. American Journal of Respiratory and Critical CareMedicine. 151, 969-974 13.Abramson MJ, Puy RM, Weiner JM. [Injection allergen immu-notherapy for asthma]. Cochrane Database Syst Rev. 2010 Aug4
  77. :CD001186. doi: 10.1002/14651858.CD001186.pub2. 14.Wilson DR, Lima MT, Durham SR. [Sublingual immunotherapyfor allergic rhinitis: systematic review and meta-analysis]. Al-lergy. 2005
  78. 60(1):4-12. 15.Penagos M, Passalacqua G, Compalati E, Baena-Cagnani CE,Orozco S, Pedroza A, et al. [Metaanalysis of the efficacy of sub-lingual immunotherapy in the treatment of allergic asthma in pe-diatric patients, 3 to 18 years of age]. Chest. 2008
  79. 133(3):599-609. 16.Calamita Z, Saconato H, Pelá AB, Atallah AN. [Efficacy of sub-lingual immunotherapy in asthma: systematic review of rando-mized-clinical trials using the Cochrane Collaboration method].Allergy. 2006
  80. 61(10):1162-72. 17.Bufe A. [Usefulness of sublingual immunotherapy in children.Drugs Today (Barc)]. 2008
  81. 44 Suppl B:61-3. 18.Bacharier LB, Boner A, Carlsen KH, Eigenmann PA, FrischerT, Götz M, et al. [Diagnosis and treatment of asthma in child-hood: a PRACTALL consensus report]. Allergy. 2008
  82. 63(1):5-34. 19.Penagos M, Compalati E, Tarantini F, Baena-Cagnani R, Hu-erta J, Passalacqua G, et al. [Efficacy of sublingual immunothe-rapy in the treatment of allergic rhinitis in pediatric patients 3to 18 years of age: a meta-analysis of randomized, placebo-con-trolled, double-blind trials]. Ann Allergy Asthma Immunol.2006
  83. 97(2):141-8. 20.Pradalier A, Basset D, Claudel A, Couturier P, Wessel F, Gal-vain S, et al. [Sublingual-swallow immunotherapy (SLIT) with astandardized five-grass-pollen extract (drops and sublingual tab-lets) versus placebo in seasonal rhinitis]. Allergy. 1999
  84. 54(8):819-28. 21.La Rosa M, Ranno C, André C, Carat F, Tosca MA, CanonicaGW. [Double-blind placebo-controlled evaluation of sublingu-al-swallow immunotherapy with standardized Parietaria judai-ca extract in children with allergic rhinoconjunctivitis]. J AllergyClin Immunol. 1999
  85. Durham SR, Yang WH, Pedersen MR, Johansen N, Rak S. [Sub-lingual immunotherapy with once-daily grass allergen tablets:a randomized controlled trial in seasonal allergic rhinoconjunc-tivitis]. J Allergy Clin Immunol. 2006
  86. 117(4):802-9. 23.Dahl R, Kapp A, Colombo G, de Monchy JG, Rak S, EmmingerW, et al. [Efficacy and safety of sublingual immunotherapy withgrass allergen tablets for seasonal allergic rhinoconjunctivitis].J Allergy Clin Immunol. 2006
  87. 118(2):434-40. 24.Bufe A, Eberle P, Franke-Beckmann E, Funck J, Kimmig M, Kli-mek L, et al. [Safety and efficacy in children of an SQ-standar-dized grass allergen tablet for sublingual immunotherapy]. J Al-lergy Clin Immunol. 2009
  88. 123(1):167-173.e7. doi:10.1016/j.jaci.2008.10.044. 25.Didier A, Malling HJ, Worm M, Horak F, Jäger S, Montagut A,et al. [Optimal dose, efficacy, and safety of once-daily sublingu-al immunotherapy with a 5-grass pollen tablet for seasonal al-lergic rhinitis]. J Allergy Clin Immunol. 2007
  89. 120(6):1338-45. 26.Dahl R, Stender A, Rak S. [Specific immunotherapy with SQ stan-dardized grass allergen tablets in asthmatics with rhinoconjunc-tivitis]. Allergy. 2006
  90. 61(2):185-90. 27.Lue KH, Lin YH, Sun HL, Lu KH, Hsieh JC, Chou MC. [Clini-cal and immunologic effects of sublingual immunotherapy in asth-matic children sensitized to mites: a double-blind, randomized,placebo-controlled study]. Pediatr Allergy Immunol.2006
  91. 17(6):408-15. 28.Pham-Thi N1, Scheinmann P, Fadel R, Combebias A, Andre C.[Assessment of sublingual immunotherapy efficacy in children withhouse dust mite-induced allergic asthma optimally controlled bypharmacologic treatment and mite-avoidance measures]. Pedi-atr Allergy Immunol. 2007
  92. 18(1):47-57. 29.Moreno-Ancillo A, Moreno C, Ojeda P, Domínguez C, Baraso na MJ, García-Cubillana A, et al. [Efficacy and quality of life withonce-daily sublingual immunotherapy with grasses plus olive pol-len extract without updosing]. J Investig Allergol Clin Immunol.2007
  93. 17(6):399-405. 30.Amar SM, Harbeck RJ, Sills M, Silveira LJ, O'Brien H, NelsonHS. [Response to sublingual immunotherapy with grass pollenextract: monotherapy versus combination in a multiallergen ext-ract]. J Allergy Clin Immunol. 2009
  94. 124(1):150-156.e1-5. doi:10.1016/j.jaci.2009.04.037. 31.Malling H. [Position paper: Immunotherapy with hymenopteravenoms. (EAACI) The European Academy of Allergology and Cli-nical Immunology]. Allergy. 1993
  95. 48(14 Suppl):36-46. 32.Bousquet J, Hejjaoui A, Dhivert H, Clauzel AM, Michel FB. [Im-munotherapy with a standardized Dermatophagoides pteronys-sinus extract. Systemic reactions during the rush protocol in pa-tients suffering from asthma]. J Allergy Clin Immunol.1989
  96. 83(4):797-802. 33.Lima MT, Wilson D, Pitkin L, Roberts A, Nouri-Aria K, Jacob-son M, et al. [Grass pollen sublingual immunotherapy for sea-sonal rhinoconjunctivitis: a randomized controlled trial]. Clin ExpAllergy. 2002
  97. 32(4):507-14. 34.Alvarez-Cuesta E, Berges-Gimeno P, González-Mancebo E, Fer-nández-Caldas E, Cuesta-Herranz J, Casanovas M. [Sublingu-al immunotherapy with a standardized cat dander extract: eva-luation of efficacy in a double blind placebo controlled study].Allergy. 2007
  98. 62(7):810-7. 35.Cox LS, Larenas Linnemann D, Nolte H, Weldon D, Finegold I,Nelson HS. [Sublingual immunotherapy: a comprehensive revi-ew]. J Allergy Clin Immunol. 2006
  99. 117(5):1021-35. 36.Dunsky EH, Goldstein MF, Dvorin DJ, Belecanech GA. [Anaphy-laxis to sublingual immunotherapy]. Allergy. 2006Oct
  100. 61(10):1235. 37.Eifan AO, Keles S, Bahceciler NN, Barlan IB. [Anaphylaxis tomultiple pollen allergen sublingual immunotherapy]. Allergy.2007
  101. 62(5):567-8. 38.Blazowski L. [Anaphylactic shock because of sublingual immu-notherapy overdose during third year of maintenance dose. Al-lergy]. 2008
  102. 63(3):374. 39.Windom HH, Lockey RF. [An update on the safety of specific im-munotherapy]. Curr Opin Allergy Clin Immunol. 2008
  103. 8(6):571-6. doi: 10.1097/ACI.0b013e32831845fb. 40.Galip N, Bahceciler N. [Rare adverse events due to house dustmite sublingual immunotherapy in pediatric practice: two casereports]. Immunotherapy. 2015
  104. 7(12):1235-9. doi:10.2217/imt.15.88. 41.Flicker S, Steinberger P, Norderhaug L, Sperr WR, Majlesi Y, Va-lent P, et al. [Conversion of grass pollen allergen-specific humanIgE into a protective IgG(1) antibody]. Eur J Immunol.2002
  105. 32(8):2156-62. 42.van Neerven RJ, Wikborg T, Lund G, Jacobsen B, Brinch-Niel-sen A, Arnved J, e t al. [Blocking antibodies induced by specificallergy vaccination prevent the activation of CD4+ T cells by in-hibiting serum-IgE-facilitated allergen presentation]. J Immunol. 1999
  106. 163 (5):29 44 -52. 43.Jutel M, Akdis M, Budak F, Aebischer-Casaulta C, Wrzyszcz M,Blaser K, et al. [IL-10 and TGF-beta cooperate in the regulatoryT cell response to mucosal allergens in normal immunity and spe-cific immunotherapy]. Eur J Immunol. 2003
  107. 33(5):1205-14. 44.Akdis CA., Blesken T, Akdis M, Wüthrich B, Blaser K. [Role ofinterleukin 10 in specific immunotherapy]. J Clin Invest. 1998
  108. 102(1): 98–106. doi: 10.1172/JCI2250. 45.Creticos PS, Adkinson NF Jr, Kagey-Sobotka A, Proud D, Me-ier HL, Naclerio RM, et al. [Nasal challenge with ragweed pol-len in hay fever patients. Effect of immunotherapy]. J Clin Invest.1985
  109. 76(6):2247-53. 46.Otsuka H, Mezawa A, Ohnishi M, Okubo K, Seki H, Okuda M.[Changes in nasal metachromatic cells during allergen immunot-herapy]. Clin Exp Allergy 1991
  110. 115–119. 47.Marcucci F, Incorvaia C, Sensi L, Di Cara G, Cadario G, Ca-valiere A, et al. [Lack of inflammatory cells in the oral mucosaof subjects undergoing sublingual immunotherapy]. Int J Immu-nopathol Pharmacol. 2008
  111. 21(3):609-13. 48.Bagnasco M, Altrinetti V, Pesce G, Caputo M, Mistrello G, Fa-lagiani P, et al. [Pharmacokinetics of Der p 2 allergen and de-rived monomeric allergoid in allergic volunteers]. Int Arch Al-lergy Immunol. 2005
  112. 138(3):197-202. 49.Bagnasco M, Passalacqua G, Villa G, Augeri C, Flamigni G, Bo-rini E, et al. [Pharmacokinetics of an allergen and a monome-ric allergoid for oromucosal immunotherapy in allergic volun-teers]. Clin Exp Allergy. 2001
  113. 31(1):54-60. 50.Nouri-Aria KT1, Wachholz PA, Francis JN, Jacobson MR, Wal-ker SM, Wilcock LK, et al. [Grass pollen immunotherapy indu-ces mucosal and peripheral IL-10 responses and blocking IgGactivity]. J Immunol. 2004
  114. 172(5):3252-9. 51.Walker SM, Varney VA, Gaga M, Jacobson MR, Durham SR.[Grass pollen immunotherapy: efficacy and safety during a 4-yearfollow-up study]. Allergy. 1995
  115. 50(5):405-13. 52.Bousquet J, Lockey R, Malling HJ, Alvarez-Cuesta E, Canoni-ca GW, Chapman MD, et al. [Allergen immunotherapy: thera-peutic vaccines for allergic diseases. World Health Organizati-on. American academy of Allergy, Asthma and Immunology]. AnnAllergy Asthma Immunol. 1998
  116. 81(5):401-5. 53.Allam JP, Peng WM, Appel T, Wenghoefer M, Niederhagen B,Bieber T, et al. [Toll-like receptor 4 ligation enforces toleroge-nic properties of oral mucosal Langerhans cells]. J Allergy ClinImmunol. 2008
  117. 121(2):368-374.e1. 54.Allam JP, Klein E, Bieber T, Novak N. [Transforming growth fac-tor-beta1 regulates the expression of the high-affinity receptorfor IgE on CD34 stem cell-derived CD1a dendritic cells in vit-ro]. J Invest Dermatol. 2004
  118. 123(4):676-82. 55.Bahceciler NN, Galip N. [Comparing subcutaneous and sublin-gual ımmunotherapy: what do we know?]. Curr Opin Allergy ClinImmunol. 2012
  119. 12(6):640-7. doi: 10. 1097/ ACI.0b013e328358d5f2. 56.Durham SR, Penagos M. [Sublingual or subcutaneous immunot-herapy for allergic rhinitis?]. J Allergy Clin Immunol.2016
  120. 137(2):339-349.e10. doi: 10.1016/j.jaci.2015.12.1298. 57.Jacobsen L, Niggemann B, Dreborg S, Ferdousi HA, Halken S,Høst A, et al. [Specific immunotherapy has long-term preventi-ve effect of seasonal and perennial asthma: 10-year follow-up onthe PAT study]. Allergy. 2007
  121. 62(8):943-8. 58.Eng PA, Borer-Reinhold M, Heijnen IA, Gnehm HP. [Twelve-yearfollow-up after discontinuation of preseasonal grass pollen immu-notherapy in childhood]. Allergy. 2006
  122. 61(2):198-201.59.Durham SR
  123. GT-08 investigators. [Sustained effects of grass pol-len AIT]. Allergy. 2011 Jul
  124. 66 Suppl 95:50-2. doi: 10.1111/j.1398-9995.2011.02639.x. 60.Marogna M, Spadolini I, Massolo A, Canonica GW, Passalac-qua G. [Long-lasting effects of sublingual immunotherapy accor-ding to its duration: a 15-year prospective study]. J Allergy ClinImmunol. 2010
  125. 126(5):969-75. doi: 10.1016/j. jaci.2010.08.030.